CTOs on the Move

Confluence Health

www.confluencehealth.org

 
Confluence Health is an integrated, rural healthcare delivery system with two hospitals, multi-specialty care in more than 30 service lines and primary care in 12 communities across North Central Washington. Our 250+ physicians and 150+ advanced practice clinicians serve an area of approximately 12,000 square miles and cover nearly every corner of the region through specialty outreach. Confluence Health is dedicated to improving our patients` health by providing safe, high-quality care in a compassionate and cost-effective manner. Core Values • Our patients are the reason for our being, and their needs will drive all of our actions. • We will treat ...
  • Number of Employees: 1K-5K
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Cerebral

Cerebral is a mental health company dedicated to improving access to treatment for anxiety and depression.

Community Health Net Medical

Community Health Net offers a range of healthcare services for newborn through geriatric patients.

Medicom Inc

Medicom Inc is a Morrisville, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cardinal Analytx Solutions

Cardinal Analytx Solutions brings together distinguished innovators and leaders collaboratively advancing into new territory to substantially address one of the most pressing human and economic challenges of our time.

Humacyte

Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte`s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte`s 6mm HAVs for AV access for performing hemodialysis was the first product candidate to receive the FDA`s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation, and the HAV technology received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.